E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011401 |
E.1.2 | Term | Crohn's disease |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To test the hypothesis that treatment with LY3074828 is superior to placebo in the proportion of subjects with endoscopic response at Week 12, defined as 50% reduction from baseline in SES-CD
Score |
|
E.2.2 | Secondary objectives of the trial |
Evaluate safety & tolerability of treatment with LY3074828
Evaluate effect of LY3074828 on the proportion of subjects with endoscopic response at Wk 52, defined as 50% reduction from baseline SES-CD score
Evaluate efficacy of LY3074828 as superior to placebo in endoscopicremission (defined as SES-CD score of <4 ilealcolonic or <2 for isolated ileal disease & no subscore >1) at Wk 12
Evaluate effect of LY3074828 on proportion of subjects with endoscopic remission (defined as SES-CD score of <4 ileal-colonic or
<2 for isolated ileal disease & no subscore >1) at Wk 52
Evaluate efficacy of treatment with LY3074828 as superior to placebo in PRO remission (defined SF ≤2.5 and AP ≤1) at Wk 12
Evaluate effect of LY3074828 on the proportion of subjects with PRO remission (defined SF ≤2.5 & AP ≤1) at Wk 52
Evaluate the effect of LY3074828 on health outcomes/quality of life measures (including: PGRS/PGRC/IBDQ & SF-36 score & FACIT-Fatigue) at Wks 12 & 52
Characterize the PK of LY3074828 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Active Crohn's Disease (CD) as determine by the SES-CD, and participant reported stool frequency and abdominal pain.
• Inadequate response or failure to tolerate at least one of the following: aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg, azathiopurine, 6-mercaptopurine, or methotrexate); or prior exposure to biologics for the treatment of CD. |
|
E.4 | Principal exclusion criteria |
• Have complications of CD such as strictures, stenoses, or any other
manifestation for which surgery might be indicated, or that could confound the evaluation of efficacy.
• Diagnosis of conditions affecting the digestive tract, such as ulcerative colitis, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome.
• Have had any kind of bowel resection, diversion, or placement of a stoma within 6 months or any other intra-abdominal surgery within 3 months prior to screening.
• Are unsuitable for inclusion in the study in the opinion of the investigator or sponsor for any reason that may compromise the subject's safety or confound data interpretation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of Participants Achieving 50% Reduction from Baseline on the Simple Endoscopic Activity Score-Crohn's Disease (SES-CD) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Discontinuation Rate
• Proportion of Participants Achieving Endoscopic Remission
• Proportion of Participants Achieving Patient Report Outcome Remission
• Mean Change from Baseline on the Patient Global Rating - Severity
(PGRS) Crohn's Disease Score
• Mean Change from Baseline on the Patient Global Rating - Change
(PGRC) Crohn's Disease Score
• Mean Change from Baseline on the Inflammatory Bowel Disease
Questionnaire (IBDQ) Score
• Mean Change from Baseline on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
• Mean Change from Baseline on the 36-Item Short Form Health Survey (SF-36) Score
• Pharmacokinetics (PK): Area Under the Curve (AUC) of LY3074828
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Time Frame: Baseline through Week 104
Time Frame: Week 12
Time Frame: Week 12
Time Frame: Baseline, Week 12
Time Frame: Baseline, Week 12
Time Frame: Baseline, Week 12
Time Frame: Baseline, Week 12
Time Frame: Baseline, Week 12
Time Frame: Baseline through Week 104
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Canada |
Czech Republic |
France |
Hungary |
Japan |
Moldova, Republic of |
Netherlands |
Poland |
Romania |
Russian Federation |
Switzerland |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is the date of the last visit or last scheduled procedure for the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |